Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
about
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapineEffects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics.Interpretation and inference in noninferiority randomized controlled trials in drug research.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.Antipsychotic agents: efficacy and safety in schizophrenia
P2860
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Feasibility of reducing the du ...... als in schizophrenia research.
@en
Feasibility of reducing the du ...... als in schizophrenia research.
@nl
type
label
Feasibility of reducing the du ...... als in schizophrenia research.
@en
Feasibility of reducing the du ...... als in schizophrenia research.
@nl
prefLabel
Feasibility of reducing the du ...... als in schizophrenia research.
@en
Feasibility of reducing the du ...... als in schizophrenia research.
@nl
P2093
P2860
P356
P1476
Feasibility of reducing the du ...... als in schizophrenia research.
@en
P2093
Deanna L Kelly
Douglas L Boggs
John M Davis
Qiaoyan Hu
Robert P McMahon
William T Carpenter
P2860
P304
P356
10.1093/SCHBUL/SBM152
P407
P577
2008-01-08T00:00:00Z